Effect of granulocyte colony-stimulating factor treatment on ex vivo neutrophil functions in nonneutropenic surgical intensive care patients.
Granulocyte colony-stimulating factor (G-CSF) preferentially stimulates growth and differentiation of neutrophil precursors and activates neutrophil functions. The aim of the present study was to investigate the functional response of the neutrophil to exogenous recombinant human G-CSF (rHuG-CSF) in nonneutropenic patients. In 30 surgical intensive care unit patients with severely impaired wound healing, leukocyte differential count, plasma G-CSF level, and a broad spectrum of neutrophil functions were monitored before (day 0), throughout (days 1 and 5), and at days 1 and 5 after stopping G-CSF treatment. G-CSF application resulted in a 3.5-fold increase in peripheral blood granulocyte count at day 5 of treatment. The mean plasma G-CSF level rose from 48 to a maximum of 2314 pg/ml at day 1 of G-CSF therapy. Neutrophil chemotaxis and stimulated lysozyme release were decreased throughout G-CSF treatment, whereas respiratory burst activity, phagocytic activity, and intracellular calcium concentration were enhanced by G-CSF. Neutrophil membrane depolarization remained unaffected. The increased count and activation state of neutrophils were associated with clinical improvement in most of these patients. Thus, G-CSF may be a useful adjuvant treatment for nonneutropenic patients with severely impaired wound healing.
Gerber
A
A
Institute of Immunology, Otto von Guericke University Magdeburg, 39120 Magdeburg, Germany. annegret.gerber@medizin.uni-magdeburg.de
Struy
H
H
Weiss
G
G
Lippert
H
H
Ansorge
S
S
Schulz
H U
HU
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001692:Biological Transport; D002118:Calcium / Q000378:metabolism; D003422:Critical Care; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000097:blood / Q000494:pharmacology*; D006801:Humans; D008297:Male; D008564:Membrane Potentials / Q000187:drug effects; D008875:Middle Aged; D009113:Muramidase / Q000378:metabolism; D009504:Neutrophils / Q000187:drug effects* / Q000378:metabolism / Q000502:physiology; D010587:Phagocytosis / Q000187:drug effects; D017382:Reactive Oxygen Species / Q000378:metabolism; D011994:Recombinant Proteins / Q000097:blood / Q000494:pharmacology
D017382:Reactive Oxygen Species; D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor; D009113:Muramidase; D002118:Calcium